Carna Biosciences, Inc. announced consolidated and non-consolidated earnings results for the year ended December 31, 2019. For the year, the company announced consolidated net sales of JPY 3,207 million compared to JPY 754 million a year ago. Ordinary profit of JPY 957 million compared to ordinary loss of JPY 1,144 million a year ago. Profit attributable to owners of parent of JPY 828 million compared to loss of JPY 1,210 million a year ago. Profit per share of JPY 76.05 compared to loss per share of JPY 125.02 a year ago. Diluted profit per share of JPY 74.51.

For the year, the company announced non-consolidated net sales of JPY 3,070 million compared to JPY 640 million a year ago. Operating profit of JPY 898 million compared to loss of JPY 1,142 million a year ago. Profit of JPY 745 million compared to ordinary loss of JPY 1,199 million a year ago. Profit per share of JPY 68.47 compared to loss per share of JPY 123.85. Diluted profit per share of JPY 67.08.

For the year ending December 31, 2020, the company forecasted consolidated net sales to be JPY 1,036 million. Operating loss to be JPY 1,779 million. Loss attributable to owners of parent of to be JPY 1,822 million. Loss per share of JPY 156.45.